UCLA and UCSF have obtained approval from the U.S. Food and Drug Administration to offer prostate-specific membrane antigen (PSMA) PET imaging to more precisely locate prostate cancer. The UCLA research team, led by nuclear medicine faculty, includes UCLA Urology’s Robert Reiter, MD, Professor and Director of the Prostate Cancer Program, and Matthew Rettig, MD, Professor and Medical Director of the Prostate Cancer Program. Both were lead investigators, along with radiation oncologists Drs. Amar Kishan and Nicholas G. Nickols, for the clinical trials that led to the FDA approval. PSMA PET imaging gives urologists the ability to more effectively stage prostate cancer in both patients newly diagnosed and those with disease recurrence, leading to improved management and care. Learn more > | Listen to Dr. Reiter’s interview with Grand Rounds in Urology >
Early detection is key to achieving cure in men with prostate cancer. At UCLA, our ability to identify men at an early stage is enhanced by our cutting edge prostate imaging program, which utilizes the most advanced MRI technology to find tumors that conventional approaches such as ultrasound can miss.
Learn about targeted biopsy >
Webinar: Making Decisions After Being Diagnosed with Early Stage Prostate Cancer, with UCLA Urologist, Dr. Christopher Saigal. Urology Webinars >